New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection
- PMID: 26496465
- DOI: 10.4155/fmc.15.99
New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection
Abstract
Background: Neurodegenerative diseases share many pathological pathways, such as abnormal protein aggregation, mitochondrial dysfunction, extensive oxidative stress and neuroinflammation. Cells have an intrinsic mechanism of protection, the Nrf2 transcriptional factor, known as the master regulator of redox homeostasis.
Results: Based on the common features of these diseases we have designed a multi-target hybrid structure derived from melatonin and ethyl cinnamate. The obtained derivatives were Nrf2 inducers and potent-free radical scavengers. These new compounds showed a very interesting neuroprotective profile in several in vitro models of oxidative stress, Alzheimer's disease and brain ischemia.
Conclusion: We have designed a new hybrid structure with complementary activities. We have identified compound 5h as an interesting Nrf2 inducer, very potent antioxidant and neuroprotectant.
Similar articles
-
Synthesis of piperlongumine analogues and discovery of nuclear factor erythroid 2-related factor 2 (Nrf2) activators as potential neuroprotective agents.J Med Chem. 2015 Jul 9;58(13):5242-55. doi: 10.1021/acs.jmedchem.5b00410. Epub 2015 Jun 26. J Med Chem. 2015. PMID: 26079183
-
Melatonin-sulforaphane hybrid ITH12674 induces neuroprotection in oxidative stress conditions by a 'drug-prodrug' mechanism of action.Br J Pharmacol. 2015 Apr;172(7):1807-21. doi: 10.1111/bph.13025. Epub 2015 Feb 10. Br J Pharmacol. 2015. PMID: 25425158 Free PMC article.
-
The role of modulation of antioxidant enzyme systems in the treatment of neurodegenerative diseases.J Enzyme Inhib Med Chem. 2016;31(sup3):194-204. doi: 10.1080/14756366.2016.1205047. Epub 2016 Jul 7. J Enzyme Inhib Med Chem. 2016. PMID: 27389167 Review.
-
Novel indole-based melatonin analogues: Evaluation of antioxidant activity and protective effect against amyloid β-induced damage.Bioorg Med Chem. 2016 Apr 15;24(8):1658-64. doi: 10.1016/j.bmc.2016.02.039. Epub 2016 Mar 2. Bioorg Med Chem. 2016. PMID: 26970662
-
Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?Free Radic Biol Med. 2008 Nov 15;45(10):1375-83. doi: 10.1016/j.freeradbiomed.2008.09.001. Epub 2008 Sep 13. Free Radic Biol Med. 2008. PMID: 18824091 Review.
Cited by
-
Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson's Disease.Antioxidants (Basel). 2022 Jan 27;11(2):247. doi: 10.3390/antiox11020247. Antioxidants (Basel). 2022. PMID: 35204129 Free PMC article.
-
Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases.Curr Neuropharmacol. 2020;18(5):348-407. doi: 10.2174/1385272823666191021124443. Curr Neuropharmacol. 2020. PMID: 31631821 Free PMC article. Review.
-
Bisavenathramide Analogues as Nrf2 Inductors and Neuroprotectors in In Vitro Models of Oxidative Stress and Hyperphosphorylation.Antioxidants (Basel). 2021 Jun 10;10(6):941. doi: 10.3390/antiox10060941. Antioxidants (Basel). 2021. PMID: 34200859 Free PMC article.
-
Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease.Sci Rep. 2017 Mar 31;7:45701. doi: 10.1038/srep45701. Sci Rep. 2017. PMID: 28361919 Free PMC article.
-
Degeneration of retina-brain components and connections in glaucoma: Disease causation and treatment options for eyesight preservation.Curr Res Neurobiol. 2022 Jun 9;3:100037. doi: 10.1016/j.crneur.2022.100037. eCollection 2022. Curr Res Neurobiol. 2022. PMID: 36685768 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical